This is a working overview of anxiolytic, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-10-25 and is reviewed periodically as new material appears.
Characterization of Selank in laboratory settings relies on standard peptide analytical techniques. Reverse-phase high-performance liquid chromatography separates the peptide from related impurities and degradation products, while mass spectrometry confirms molecular identity through accurate mass measurement. Amino acid analysis and peptide sequencing verify the primary structure when reference material is unavailable. Because Selank is a short chain, fragmentation-based analysis produces a diagnostic ion pattern that supports confident identification.
Peptide stability depends strongly on temperature, moisture, and pH. Lyophilized Selank is generally most stable when stored cold and dry, with freezer temperatures commonly used for long-term storage. In solution, the compound is susceptible to hydrolysis and to microbial growth if it is not handled aseptically. The C-terminal proline-rich extension appears to slow enzymatic cleavage relative to tuftsin, though quantitative degradation rates vary with the matrix and the conditions tested. Published stability data specific to Selank remain sparse.
Quality assessment of Selank samples typically combines purity determination with identity confirmation and counter-ion analysis. Purity is usually reported as a percentage by chromatographic area, with values above 95 percent often quoted for research-grade material. Water content and residual solvents are checked in lyophilized batches because they affect both stability and accurate mass determination. A reported purity figure does not by itself establish that a sample is the intended sequence, so orthogonal methods are needed to rule out sequence isomers or truncation products.
Reported activity for Selank centers on anxiolytic and nootropic effects. Russian clinical reports describe use in anxiety and in cognitive or attention-related complaints. Most of this evidence comes from studies conducted by the same research groups that developed the peptide. Independent replication in other countries remains limited, and no major Western regulatory agency has approved the compound for any indication. The gap between local reports and external verification is a recurring point in discussions of the peptide.
Tuftsin, the parent structure, is a naturally occurring immunomodulatory tetrapeptide released from the Fc region of immunoglobulin G by spleen enzymes. Selank extends this four-residue sequence with three additional amino acids. The stated rationale is that the added tail slows enzymatic breakdown and may influence receptor interactions. How the full heptapeptide behaves at the molecular level is not firmly established, and proposed mechanisms often involve indirect modulation of neurotransmitter or immune signaling rather than a single defined target.
Selank is a synthetic heptapeptide developed in Russia. Its sequence is Thr-Lys-Pro-Arg-Pro-Gly-Pro, a seven-residue chain built around the natural tetrapeptide tuftsin. Researchers at the Institute of Molecular Genetics of the Russian Academy of Sciences first described the compound in the mid-1990s. The design combined the tuftsin core with an added Pro-Gly-Pro tail, a modification intended to extend the molecule's stability in biological fluids. Published work on the peptide has appeared mainly in Russian-language journals.
| Property | Value | Notes |
|---|---|---|
| Typical storage temperature | -20 °C or below | For lyophilized powder, long term |
| Common analytical method | Reverse-phase HPLC | Usually paired with mass spectrometry |
| Typical reported purity | At or above 95 percent by area | Research-grade material |
| Aqueous solubility | High | Solutions used in laboratory assays |
| Moisture sensitivity | Hydrolyzes in solution | Aseptic handling reduces degradation |
Selank is a synthetic heptapeptide developed in Russia during the 1990s. Researchers at the Institute of Molecular Genetics of the Russian Academy of Sciences designed it as a stabilized analog of tuftsin, a naturally occurring immunomodulatory tetrapeptide. The compound has been studied primarily for its reported anxiolytic and nootropic effects. It remains largely unknown in Western pharmacology and is not approved as a medicine by major regulators such as the FDA or the EMA.
The primary structure of Selank is Thr-Lys-Pro-Arg-Pro-Gly-Pro, corresponding to the molecular formula C33H57N11O9 and a monoisotopic mass of roughly 751.9 daltons. The N-terminal threonine and the arginine residue in the fourth position are shared with tuftsin, which carries the sequence Thr-Lys-Pro-Arg. The three additional residues at the C-terminus, Pro-Gly-Pro, extend the chain and are associated with greater resistance to enzymatic degradation. This extension also separates Selank from the shorter parent peptide.
Naming conventions place Selank in the same research family as Semax, another Russian-developed peptide investigated for cognitive effects. The two compounds share a lineage but differ in sequence and in the biological systems proposed as their targets. Semax descends from ACTH fragments, whereas Selank descends from tuftsin. Publications sometimes identify Selank by its full peptide sequence or by laboratory codes rather than one uniform trade name. Because replication outside Russia is limited, reports on its properties are best read alongside the study design and the purity of the material tested.
Published work on this peptide almost always uses intranasal delivery, with drops or a spray applied to the nasal mucosa. Some animal experiments have used subcutaneous or intraperitoneal injection, and a smaller number have compared routes directly. Oral administration is not a focus of the literature, because short peptides of this size are broken down by digestive enzymes and cross intestinal barriers poorly. How much of an intranasal dose reaches the bloodstream intact in humans remains an open question.
Animal studies have examined behaviour in tests of anxiety, memory retention and stress response, and several report changes in neurotrophic or neurotransmitter-related markers. The human evidence base is much smaller, consisting mainly of short trials conducted in Russia with limited reporting in English-language journals. Sample sizes are modest and outcome measures vary between studies, so the findings are best described as preliminary. Independent replication under modern trial standards has not been widely reported.
Outside its country of origin the compound is generally handled as a research chemical rather than an approved medicine. No regulatory approval from the United States Food and Drug Administration or the European Medicines Agency has been granted for human use. Identity and purity are normally checked by reverse-phase high-performance liquid chromatography, with mass spectrometry used to confirm the molecular mass. Lyophilised material is stored cold and desiccated, and repeated freeze-thaw cycles are avoided.
Computational proteomics is both an interdisciplinary field and a specialization of bioinformatics which uses computational techniques to study the proteome; in particular, computational proteomics is based on peptides identification techniques and allows to integrate vast quantities of heterogeneous data referred to proteins (e.g., identification of proteins, quantification, protein-protein interactions, structures...) and genomics (e.g., expression of genes and expression of proteins). The results of both proteomics and computational proteomics are used by biomedical engineering, biotechnology and Agri-Food Studies.
High-energy radiation from space is much stronger at high altitudes than at sea level. The radiation exposure of flight crews and air travelers is therefore increased. The International Commission on Radiological Protection (ICRP) has issued recommendations for dose limits, which were incorporated into European law in 1996 and into the German Radiation Protection Ordinance in 2001. Radiation exposure is particularly high when flying in the polar regions or over the polar route. The average annual effective dose for aviation personnel was 1.9 mSv in 2015 and 2.0 mSv in 2016. The highest annual personal dose was 5.7 mSv in 2015 and 6.0 mSv in 2016. The collective dose for 2015 was about 76 person-Sv. This means that flight personnel are among the occupational groups in Germany with the highest radiation exposure in terms of collective dose and average annual dose. This group also includes frequent flyers, with Thomas Stuker holding the "record" - also in terms of radiation exposure - by reaching the 10 million mile mark with United Airlines MileagePlus on 5,900 flights between 1982 and the summer of 2011. In 2017, he passed the 18 million mile mark. The program EPCARD (European Program Package for the Calculation of Aviation Route Dose) was developed at the University of Siegen and the Helmholtz Munich and can be used to calculate the dose from all components of natural penetrating cosmic radiation on any flight route and flight profile - also online.
== Select publications == Meindl, Kathrin; Schmiederer, Timo; Schneider, Kathrin; Reicke, Andreas; Butz, Diane; Keller, Simone; et al. (February 2010). "Labyrinthopeptine – eine neue Klasse carbacyclischer Lantibiotika". Angewandte Chemie (in German). 122 (6): 1169–1173. doi:10.1002/ange.200905773. Schadt, Heiko S.; Schadt, Simone; Oldach, Florian; Süssmuth, Roderich D. (February 18, 2009). "2-Amino-2-deoxyisochorismate Is a Key Intermediate in Bacillus subtilis p-Aminobenzoic Acid Biosynthesis". Journal of the American Chemical Society. 131 (10). doi:10.1021/ja809283u. Dettner, Frank; Hänchen, Anne; Schols, Dominique; Toti, Luigi; Nußer, Antje; Süssmuth, Roderich D. (February 2009). "Totalsynthese des antiviralen Peptidantibiotikums Feglymycin". Angewandte Chemie (in German). 121 (10): 1888–1893. doi:10.1002/ange.200804130. Bister, Bojan; Bischoff, Daniel; Ströbele, Markus; Riedlinger, Julia; Reicke, Andreas; Wolter, Falko; et al. (May 2004). "Abyssomicin C—A Polycyclic Antibiotic from a Marine Verrucosispora Strain as an Inhibitor of the p ‐Aminobenzoic Acid/Tetrahydrofolate Biosynthesis Pathway". Angewandte Chemie International Edition. 43 (19): 2574–2576. doi:10.1002/anie.200353160. Bister, Bojan; Bischoff, Daniel; Nicholson, Graeme J.; Valdebenito, Marianne; Schneider, Kathrin; Winkelmann, Günther; et al. (August 2004). "The structure of salmochelins: C-glucosylated enterobactins of Salmonella enterica §". Biometals. 17 (4): 471–481. doi:10.1023/B:BIOM.0000029432.69418.6a.
It has been indicated that one Mn2+ ion is tightly bound to His370, while the second is loosely bound to Asp276. Human prolidase has four crystal structures, HsProl-Mn, HsProl-Na-GlyPro, HsProl-Mg-LeuPro, and HsProl-Mn-Pro. The first of these structures, HsProl-Mn, pertains to the activity of serum prolidase before binding the substrate. Furthermore, HsProl-Na-GlyPro results from substrate degradation caused by the exchange of the Mn2+ ion with Na+. This is caused by the substrate GlyPro binding to the enzyme. The third crystal structure of serum prolidase is HsProl-Mg-LeuPro. This structure functions similarly to HsProl-Na-GlyPro; however, the substrate utilized in this structure is LeuPro. Additionally, Mn2+ is replaced by Mg2+. These differences cause the structure to be more stable with a lower turnover rate. The final crystal structure of serum prolidase is HsProl-Mn-Pro, which employs Pro as the substrate. This Pro comes from the reaction being catalyzed by this enzyme. The crystal structure of prolidase is well-researched and recorded in the Protein Data Bank.
Sources: en.wikipedia.org
=== Lung disease === Active alveolitis is often treated with pulses of cyclophosphamide, often together with a small dose of steroids. The benefit of this intervention is modest. Pulmonary hypertension may be treated with epoprostenol, treprostinil, bosentan, and possibly aerolized iloprost. Nintedanib was approved for use in the United States Food and Drug Administration on September 6, 2019, to slow the rate of decline in pulmonary function in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD).
=== Infections === Certain viral and bacterial infections have been linked to autoimmune diseases. For instance, research suggests that the bacterium that causes strep throat, Streptococcus pyogenes, might trigger rheumatic fever, an autoimmune response affecting the heart. Similarly, some studies propose a link between the Epstein–Barr virus, responsible for mononucleosis, and the subsequent development of multiple sclerosis or lupus.
=== Chemical === Flerovium is the heaviest known member of group 14, below lead, and is projected to be the second member of the 7p series of elements. Nihonium and flerovium are expected to form a very short subperiod corresponding to the filling of the 7p1/2 orbital, coming between the filling of the 6d5/2 and 7p3/2 subshells. Their chemical behaviour is expected to be very distinctive: nihonium's homology to thallium has been called "doubtful" by computational chemists, while flerovium's to lead has been called only "formal". The first five group 14 members show a +4 oxidation state and the latter members have increasingly prominent +2 chemistry due to onset of the inert pair effect. For tin, the +2 and +4 states are similar in stability, and lead(II) is the most stable of all the chemically well-understood +2 oxidation states in group 14. The 7s orbitals are very highly stabilized in flerovium, so a very large sp3 orbital hybridization is needed to achieve a +4 oxidation state, so flerovium is expected to be even more stable than lead in its strongly predominant +2 oxidation state and its +4 oxidation state should be highly unstable.
Sources: en.wikipedia.org
=== Ischemic stroke === Some preliminary research suggested that citicoline may reduce the rates of death and disability following an ischemic stroke. However, the largest citicoline clinical trial to date (a randomised, placebo-controlled, sequential trial of 2,298 patients with moderate-to-severe acute ischaemic stroke in Europe), found no benefit of administering citicoline on survival or recovery from stroke. A meta-analysis of seven trials reported no statistically significant benefit for long-term survival or recovery.
In 2010, Ian Read was named CEO. In February 2011, Pfizer announced the closure of its UK research and development facility (formerly also a manufacturing plant) in Sandwich, Kent, which at the time employed 2,400 people. In March 2011, Pfizer acquired King Pharmaceuticals for $3.6 billion in cash. King produced emergency injectables such as the EpiPen. On September 4, 2012, the FDA approved bosutinib (Bosulif) for chronic myelogenous leukemia (CML), a rare type of leukemia and a blood and bone marrow disease that affects primarily older adults. In November 2012, Pfizer received approval from the Food and Drug Administration for Xeljanz, a tofacitinib, for rheumatoid arthritis and ulcerative colitis. The drug had sales of $1.77 billion in 2018, and in January 2019, it was the top drug in the United States for direct-to-consumer advertising, passing adalimumab (Humira). In 2023, the Institute for Clinical and Economic Review (ICER) identified Xeljanz (tofacitinib) as one of five high-expenditure drugs that experienced significant net price increases without new clinical evidence to justify the hikes. Specifically, Xeljanz's wholesale acquisition cost rose by 6%, leading to an additional $72 million in costs to U.S. payers. On February 1, 2013, Zoetis, the Agriculture Division of Pfizer and later Pfizer Animal Health, became a public company via an initial public offering, raising $2.2 billion. Later in 2013, Pfizer completed the corporate spin-off of its remaining stake in Zoetis.
== Awards and recognition == Fellow, American Association for the Advancement of Science (1995) Fellow, Academy of Toxicological Sciences (2000) Public Communications Award, Society of Toxicology (2014) Excellence in Pharmacology/Toxicology Lifetime Award, PhRMA Foundation (2015) David Rall Medal, National Academy of Medicine (2020) Merit Award, Society of Toxicology (2024)
Sources: en.wikipedia.org
The most common approach combines reverse-phase liquid chromatography with mass spectrometry. Chromatography separates the components while mass spectrometry confirms the molecular mass. Peptide sequencing or tandem mass analysis can further verify the amino acid order.
Lyophilized powder is usually kept frozen and protected from moisture. Solutions are less stable and are often used promptly or divided into aliquots to avoid repeated freeze-thaw cycles. Exact shelf-life values depend on purity and handling.
No. A purity figure derived from chromatographic area does not prove the amino acid sequence. Identity requires an orthogonal method such as mass spectrometry or sequencing. Truncated or isomerized peptides can co-elute with the target compound.
Selank is a synthetic peptide made of seven amino acids. It is modeled on tuftsin, a natural tetrapeptide, with an added three-residue tail. It is not a small-molecule drug.